IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 07, 2025.
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals reported its Q1 FY26 (quarter ended 30 June 2025) unaudited results, with revenue from operations rising to Rs. 551.69 crore from Rs. 502.38 crore a year earlier, a growth of about 9.8%. Profit after tax grew to Rs. 33.96 crore (vs Rs. 29.68 crore) and EPS came in at Rs. 1.16 (vs Rs. 1.01). The pharmaceutical segment contributed Rs. 329.33 crore in revenue while chemicals contributed Rs. 281.06 crore. The board also approved setting up a wholly owned subsidiary in the United Kingdom to expand into the UK and EU markets. Additionally, the company will set up a new Unit 9B dedicated to manufacturing Minoxidil and its intermediates with 120 MTPA capacity, involving a small capex of Rs. 5.50 crore to be funded through internal accruals and expected to be completed by December 2025.
Steady double-digit profit growth and a clean quarterly beat support a positive view for shareholders. The UK subsidiary and the Minoxidil expansion signal the company's push to scale globally and strengthen its pharma API portfolio, though the Rs. 5.5 crore capex is small and unlikely to materially move the stock on its own.